AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22354999 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-instruction for CFS in subgroup with physical disabilities (SF-36 physical functioning ≤70)
Number of subjects: 123
Study 19267956 — intervention group
Group type: EXPERIMENTAL
Intervention: left PET-guided rTMS (n = 9)
Number of subjects: 48
Study 19267956 — intervention group
Group type: EXPERIMENTAL
Intervention: standard rTMS (n = 18)
Number of subjects: 48
Study 19267956 — intervention group
Group type: EXPERIMENTAL
Intervention: stimulation over dorsolateral prefrontal cortex (BA 9-46, n = 15)
Number of subjects: 48
Study 19267956 — intervention group
Group type: COMPARATOR
Intervention: sham rTMS (n = 14)
Number of subjects: 48
Study 19267956 — intervention group
Group type: EXPERIMENTAL
Intervention: right PET-guided rTMS
Number of subjects: 48
Study 17666597 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG 2 g/kg/wk (group A)
Number of subjects: 73
Study 17666597 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG 1 g/kg/wk plus prednisone 0.5 mg/kg/d (group B)
Number of subjects: 73
Study 17666597 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 73
Study 16146257 — intervention group
Group type: EXPERIMENTAL
Intervention: TEA with 0.2% ropivacaine and ipsilateral brachial plexus block (BPB)
Number of subjects: 50
Study 16146257 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 50
Study 11823672 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL (100 mg once daily)
Number of subjects: 0
Study 11823672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9935096 — intervention group
Group type: EXPERIMENTAL
Intervention: LPA therapy at 20 J/cm2, double pulsed at a repetition rate of one Hz
Number of subjects: 28
Study 9935096 — intervention group
Group type: EXPERIMENTAL
Intervention: LPA therapy at 20 J/cm2, single pulsed with a pulse duration of 5 msec followed by 23.4% hypertonic saline sclerotherapy
Number of subjects: 28
Study 8785378 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg selegiline tablet
Number of subjects: 0
Study 8785378 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg selegiline solution
Number of subjects: 0
Study 8785378 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both dosage forms
Number of subjects: 0
Study 8785378 — intervention group
Group type: COMPARATOR
Intervention: Both groups (tablet and solution)
Number of subjects: 0
Study 2222626 — intervention group
Group type: EXPERIMENTAL
Intervention: New technique (n = 46)
Number of subjects: 90
Study 2222626 — intervention group
Group type: COMPARATOR
Intervention: Shirodkar operation (n = 44)
Number of subjects: 90
Study 16203 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 67
Study 30927150 — intervention group
Group type: EXPERIMENTAL
Intervention: BioRoot RCS
Number of subjects: 66
Study 30927150 — intervention group
Group type: EXPERIMENTAL
Intervention: Totalfill BC
Number of subjects: 66
Study 30927150 — intervention group
Group type: EXPERIMENTAL
Intervention: AH Plus
Number of subjects: 66
Study 30927150 — intervention group
Group type: COMPARATOR
Intervention: No sealer (Control)
Number of subjects: 66
Study 27999018 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A (0.3‐0.6 mg/kg twice daily) with ART (tenofovir, emtricitabine and lopinavir/ritonavir) for 8 weeks
Number of subjects: 20
Study 27999018 — intervention group
Group type: COMPARATOR
Intervention: ART alone (tenofovir, emtricitabine and lopinavir/ritonavir)
Number of subjects: 20
Study 26310984 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl
Number of subjects: 9
Study 26310984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 23263720 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa‐2a plus ribavirin (135‐180 µg subcutaneously/week and 800‐1200 mg/day orally)
Number of subjects: 168
Study 23263720 — intervention group
Group type: COMPARATOR
Intervention: interferon alfa‐2b plus ribavirin (300‐500 million units, once every other day and 800‐1200 mg/day)
Number of subjects: 168
Study 23263720 — intervention group
Group type: EXPERIMENTAL
Intervention: RVR (Rapid Virological Response)
Number of subjects: 168
Study 23263720 — intervention group
Group type: EXPERIMENTAL
Intervention: No RVR
Number of subjects: 168
Study 23263720 — intervention group
Group type: EXPERIMENTAL
Intervention: EVR (Early Virological Response)
Number of subjects: 168
Study 23263720 — intervention group
Group type: EXPERIMENTAL
Intervention: No EVR
Number of subjects: 168
Study 20456906 — intervention group
Group type: COMPARATOR
Intervention: E alone (epinephrine)
Number of subjects: 44
Study 20456906 — intervention group
Group type: EXPERIMENTAL
Intervention: E+V (epinephrine plus vasopressin)
Number of subjects: 44
Study 20456906 — intervention group
Group type: EXPERIMENTAL
Intervention: E+V+N (epinephrine plus vasopressin plus nitroglycerin)
Number of subjects: 44
Study 19168868 — intervention group
Group type: EXPERIMENTAL
Intervention: QuBE score
Number of subjects: 790
Study 16904092 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 22
Study 16904092 — intervention group
Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 22
Study 15146409 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg subcutaneously every other week
Number of subjects: 619
Study 15146409 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 20 mg subcutaneously every week
Number of subjects: 619
Study 15146409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 619
Study 14723388 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG criteria (Sokolow‐Lyon and Cornell voltage with repolarisation criteria)
Number of subjects: 890
Study 14723388 — intervention group
Group type: EXPERIMENTAL
Intervention: Cornell criteria
Number of subjects: 890
Study 14723388 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG
Number of subjects: 890
Study 10467196 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (25 mg twice daily, n = 14)
Number of subjects: 21
Study 10467196 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 7)
Number of subjects: 21
Study 7601400 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus somatostatin (250 micrograms injection followed by 250 micrograms/h infusion)
Number of subjects: 32
Study 7601400 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous somatostatin (250 micrograms/h infusion)
Number of subjects: 32
Study 7601400 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous somatostatin (500 micrograms/h infusion)
Number of subjects: 32
Study 7601400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 2210972 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg at 12-hour intervals (30 subjects)
Number of subjects: 77
Study 2210972 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 250 mg at 12-hour intervals (24 subjects)
Number of subjects: 77
Study 2210972 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 100 mg at 12-hour intervals for three days (23 subjects with uncomplicated UTI)
Number of subjects: 77
Study 356181 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalexin
Number of subjects: 91
Study 356181 — intervention group
Group type: COMPARATOR
Intervention: Co-trimoxazole
Number of subjects: 91
Study 31331065 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially hydrolysed whey formula with 1.8 g protein/100 kcal (pHF1.8)
Number of subjects: 207
Study 31331065 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially hydrolysed whey formula with 2.27 g protein/100 kcal (pHF2.27)
Number of subjects: 207
Study 31331065 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially hydrolysed whey formula with 2.0 g protein/100 kcal (pHF2.0)
Number of subjects: 207
Study 31331065 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (pHF1.8, pHF2.0, pHF2.27)
Number of subjects: 207
Study 28698351 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg intranasal ketamine
Number of subjects: 0
Study 28698351 — intervention group
Group type: COMPARATOR
Intervention: Volume-matched intranasal normal saline (placebo)
Number of subjects: 0
Study 28698351 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard analgesic therapy (for all participants)
Number of subjects: 0
Study 23807349 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine-timolol fixed combination therapy (FCBT)
Number of subjects: 60
Study 23807349 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide-timolol fixed combination therapy (FCDT)
Number of subjects: 60
Study 23725301 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissolved oxygen dressing (OxygeneSys™‐Continuous)
Number of subjects: 50
Study 21542774 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stage tract dilation (group 2)
Number of subjects: 48
Study 21542774 — intervention group
Group type: COMPARATOR
Intervention: Gradual tract dilation (group 1)
Number of subjects: 48
Study 19523908 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal vaccination (0.1 ml of trivalent inactivated influenza vaccine, 3 microg of hemagglutinin per strain)
Number of subjects: 126
Study 19523908 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular vaccination (0.25 ml of trivalent inactivated influenza vaccine, 7.5 microg of hemagglutinin per strain)
Number of subjects: 126
Study 19523908 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (ID and IM)
Number of subjects: 126
Study 17497710 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth Eating Disorder Examination-Questionnaire (YEDE-Q)
Number of subjects: 35
Study 15458016 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP
Number of subjects: 8
Study 15458016 — intervention group
Group type: COMPARATOR
Intervention: No PEEP (Control)
Number of subjects: 8
Study 11442735 — intervention group
Group type: EXPERIMENTAL
Intervention: Debridement group (supra‐ and subgingival ultrasonic instrumentation without analgesia)
Number of subjects: 105
Study 11442735 — intervention group
Group type: COMPARATOR
Intervention: SRP group (scaling/root planing with local analgesia)
Number of subjects: 105
Study 11442735 — intervention group
Group type: EXPERIMENTAL
Intervention: Debridement group
Number of subjects: 105
Study 11442735 — intervention group
Group type: COMPARATOR
Intervention: SRP group
Number of subjects: 105
Study 9512674 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 10 micrograms/kg
Number of subjects: 593
Study 9512674 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms/kg
Number of subjects: 593
Study 8070610 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (10-20 mg/day)
Number of subjects: 35
Study 8070610 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (50-100 mg/day)
Number of subjects: 35
Study 31014947 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastric bypass surgery
Number of subjects: 2495
Study 31014947 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 2495
Study 31014947 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 2495
Study 31014947 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 2495
Study 31014947 — intervention group
Group type: EXPERIMENTAL
Intervention: History of smoking
Number of subjects: 2495
Study 31014947 — intervention group
Group type: EXPERIMENTAL
Intervention: Being single
Number of subjects: 2495
Study 31014947 — intervention group
Group type: EXPERIMENTAL
Intervention: Being first-generation immigrant
Number of subjects: 2495
Study 31014947 — intervention group
Group type: EXPERIMENTAL
Intervention: Elementary occupation
Number of subjects: 2495
Study 27864832 — intervention group
Group type: EXPERIMENTAL
Intervention: Colistin (2.5 million IU intravenous dose)
Number of subjects: 0
Study 27864832 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 26105708 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-release non-fatal overdose among PWID
Number of subjects: 1051
Study 26105708 — intervention group
Group type: COMPARATOR
Intervention: Post-release non-fatal overdose among all ex-prisoners
Number of subjects: 1051
Study 26105708 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-release predictors of overdose among PWID
Number of subjects: 1051
Study 26105708 — intervention group
Group type: EXPERIMENTAL
Intervention: Risky alcohol use in the year before prison
Number of subjects: 1051
Study 23652464 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial non-pharmacological prevention program for hip fracture
Number of subjects: 1004
Study 23652464 — intervention group
Group type: COMPARATOR
Intervention: Control group with no intervention
Number of subjects: 1004
Study 23652464 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial non-pharmacological prevention program
Number of subjects: 1004
Study 21791965 — intervention group
Group type: EXPERIMENTAL
Intervention: hm gamma-PGA treatment in rats (NFP or HFP) for 4 weeks
Number of subjects: 32
Study 21791965 — intervention group
Group type: COMPARATOR
Intervention: hm gamma-PGA supplementation (150 mg/day) in humans for 8 weeks
Number of subjects: 32
Study 19332187 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months clopidogrel therapy after DES implantation
Number of subjects: 6000
Study 19332187 — intervention group
Group type: COMPARATOR
Intervention: 12 months clopidogrel therapy after DES implantation
Number of subjects: 6000
Study 16935786 — intervention group
Group type: EXPERIMENTAL
Intervention: Analytic accounting system of the hospital
Number of subjects: 0
Study 16935786 — intervention group
Group type: COMPARATOR
Intervention: French Diagnosis Related Group (DRG) cost databases
Number of subjects: 0
Study 16935786 — intervention group
Group type: COMPARATOR
Intervention: French DRG prospective payment system
Number of subjects: 0
Study 15190231 — intervention group
Group type: EXPERIMENTAL
Intervention: SR 142801 (NK3 receptor antagonist)
Number of subjects: 24
Study 15190231 — intervention group
Group type: EXPERIMENTAL
Intervention: SR 48692 (neurotensin receptor antagonist)
Number of subjects: 24
Study 15190231 — intervention group
Group type: EXPERIMENTAL
Intervention: SR 141716 (cannabinoid receptor antagonist)
Number of subjects: 24
Study 15190231 — intervention group
Group type: COMPARATOR
Intervention: Levodopa (single dose)
Number of subjects: 24
Study 10665517 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide 0.3%
Number of subjects: 0
Study 10665517 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1%
Number of subjects: 0
Study 10665517 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide 2%
Number of subjects: 0
Study 10665517 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide 3%
Number of subjects: 0
Study 10665517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9305326 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type B (BotB) 2,500 U
Number of subjects: 122
Study 9305326 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type B (BotB) 5,000 U
Number of subjects: 122
Study 9305326 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type B (BotB) 10,000 U
Number of subjects: 122
Study 9305326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 8313401 — intervention group
Group type: EXPERIMENTAL
Intervention: Brofaromine
Number of subjects: 0
Study 8313401 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine
Number of subjects: 0
Study 2871849 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium (0.135-0.5 mg kg‐1)
Number of subjects: 70
Study 2871849 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium (0.02-0.1 mg kg‐1)
Number of subjects: 70
Study 2871849 — intervention group
Group type: COMPARATOR
Intervention: Comparison of equipotent doses of atracurium and vecuronium
Number of subjects: 70
Study 31210635 — intervention group
Group type: EXPERIMENTAL
Intervention: Sound therapy (maskers)
Number of subjects: 18
Study 31210635 — intervention group
Group type: COMPARATOR
Intervention: No sound therapy (control)
Number of subjects: 18
Study 29538053 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 50
Study 29538053 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone
Number of subjects: 50
Study 26540396 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 1125
Study 26540396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1125
Study 26540396 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (female subgroup)
Number of subjects: 1125
Study 26540396 — intervention group
Group type: COMPARATOR
Intervention: Placebo (female subgroup)
Number of subjects: 1125
Study 26540396 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone and Placebo
Number of subjects: 1125
Study 23832575 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonate (Bis)
Number of subjects: 15
Study 23832575 — intervention group
Group type: COMPARATOR
Intervention: Calcitriol (VD)
Number of subjects: 15
Study 23832575 — intervention group
Group type: COMPARATOR
Intervention: Menatetrenone (VK)
Number of subjects: 15
Study 22711499 — intervention group
Group type: EXPERIMENTAL
Intervention: 238 g PEG + 1.9 L Gatorade
Number of subjects: 136
Study 22711499 — intervention group
Group type: COMPARATOR
Intervention: 4 L of PEG-ELS
Number of subjects: 136
Study 20472937 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower oxygen saturation target range (85 to 89%)
Number of subjects: 1316
Study 20472937 — intervention group
Group type: COMPARATOR
Intervention: Higher oxygen saturation target range (91 to 95%)
Number of subjects: 1316
Study 18721566 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (2 x 10(6) kallikrein inhibiting units (KIU) loading dose, 0.5 x 10(6) KIU/hour)
Number of subjects: 120
Study 18721566 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 120
Study 16036509 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten challenge
Number of subjects: 41
Study 16036509 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free diet
Number of subjects: 41
Study 16036509 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-coeliac subjects)
Number of subjects: 41
Study 16036509 — intervention group
Group type: COMPARATOR
Intervention: Control group (classical coeliac disease patients)
Number of subjects: 41
Study 11954952 — intervention group
Group type: EXPERIMENTAL
Intervention: Colforsin (0.5mg x kg(‐1) min(‐1) for 6 hours)
Number of subjects: 26
Study 11954952 — intervention group
Group type: COMPARATOR
Intervention: Control (no colforsin treatment)
Number of subjects: 26
Study 10623332 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebuhaler pressurized metered dose inhaler (pMDI)
Number of subjects: 198
Study 10623332 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbuhaler dry powder inhaler
Number of subjects: 198
Study 7494824 — intervention group
Group type: COMPARATOR
Intervention: Pure water (control solution)
Number of subjects: 8
Study 7494824 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol 2.264 g/200 ml
Number of subjects: 8
Study 7494824 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol 10 g/200 ml
Number of subjects: 8
Study 2188794 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid-rich fish oil (MaxEPA', 2.8 g EPA daily)
Number of subjects: 10
Study 2188794 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 10
Study 7003448 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.96 g single oral dose of co-trimoxazole
Number of subjects: 64
Study 7003448 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.92 g single oral dose of co-trimoxazole
Number of subjects: 64
Study 7003448 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.88 g single oral dose of co-trimoxazole
Number of subjects: 64
Study 7003448 — intervention group
Group type: COMPARATOR
Intervention: Conventional five-day course of co-trimoxazole
Number of subjects: 64
Study 31999147 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol group (peak BAC of 0.07%)
Number of subjects: 40
Study 31999147 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 40
Study 31999147 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol group
Number of subjects: 40
Study 31358709 — intervention group
Group type: EXPERIMENTAL
Intervention: HyFlex™ EDM (HFEDM)
Number of subjects: 22
Study 31358709 — intervention group
Group type: COMPARATOR
Intervention: ProTaper Next (PTN)
Number of subjects: 22
Study 28282504 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 60
Study 28282504 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical treatment
Number of subjects: 60
Study 28282504 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 27298538 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-mucosal injection of 0.5 mg/kg ketamine hydrochloride
Number of subjects: 20
Study 27298538 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infiltration (Placebo)
Number of subjects: 20
Study 24632042 — intervention group
Group type: EXPERIMENTAL
Intervention: EG 500 (500 mg of encapsulated C. xanthocarpa)
Number of subjects: 156
Study 24632042 — intervention group
Group type: EXPERIMENTAL
Intervention: EG 1000 (1000 mg of encapsulated C. xanthocarpa)
Number of subjects: 156
Study 24632042 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG, placebo treatment)
Number of subjects: 156
Study 22853706 — intervention group
Group type: EXPERIMENTAL
Intervention: Branching case pathways present with structured clinical reasoning feedback present
Number of subjects: 112
Study 22853706 — intervention group
Group type: EXPERIMENTAL
Intervention: Branching case pathways present with structured clinical reasoning feedback absent
Number of subjects: 112
Study 22853706 — intervention group
Group type: EXPERIMENTAL
Intervention: Branching case pathways absent with structured clinical reasoning feedback present
Number of subjects: 112
Study 22853706 — intervention group
Group type: EXPERIMENTAL
Intervention: Branching case pathways absent with structured clinical reasoning feedback absent
Number of subjects: 112
Study 22853706 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 112
Study 22853706 — intervention group
Group type: EXPERIMENTAL
Intervention: One centre
Number of subjects: 112